AHA/ASA guideline recommendations for prevention of stroke: Difference between revisions
< AHA
| Line 11: | Line 11: | ||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Genetic screening | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.'''Genetic screening to determine risk for [[myopathy]] is not recommended when initiation of [[statin]] therapy is being considered ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' Genetic screening of the general population for the prevention of a first stroke is not recommended ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>''' | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''3.'''Screening for intracranial aneurysms in every car- rier of [[autosomal-dominant polycystic kidney disease]] or [[Ehlers-Danlos|Ehlers-Danlos type IV mutations]] is not recommended ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>''' | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''4.''' Noninvasive screening for unruptured intracranial aneurysms in patients with no more than 1 relative with [[SAH]] or intracranial aneurysms is not recommended ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
| Line 40: | Line 40: | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' Noninvasive screening for unruptured intracranial aneurysms in patients with cervical [[fibromuscular dysplasia]] may be considered''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' Noninvasive screening for unruptured intracranial aneurysms in patients with cervical [[fibromuscular dysplasia]] may be considered''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''6.''' harmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |} | ||
Revision as of 20:29, 17 November 2016
|
Ischemic Stroke Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
AHA/ASA guideline recommendations for prevention of stroke On the Web |
|
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke |
|
FDA on AHA/ASA guideline recommendations for prevention of stroke |
|
CDC on AHA/ASA guideline recommendations for prevention of stroke |
|
AHA/ASA guideline recommendations for prevention of stroke in the news |
|
Blogs on AHA/ASA guideline recommendations for prevention of stroke |
|
Risk calculators and risk factors for AHA/ASA guideline recommendations for prevention of stroke |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
2014 AHA/ASA Guidelines for the Primary Prevention of Stroke[1]
Genetic Factors: Recommendations
| Class III (Harm) |
| "1.Genetic screening to determine risk for myopathy is not recommended when initiation of statin therapy is being considered (Level of Evidence: C)" |
| "2. Genetic screening of the general population for the prevention of a first stroke is not recommended (Level of Evidence: C)" |
| "3.Screening for intracranial aneurysms in every car- rier of autosomal-dominant polycystic kidney disease or Ehlers-Danlos type IV mutations is not recommended (Level of Evidence: C)" |
| "4. Noninvasive screening for unruptured intracranial aneurysms in patients with no more than 1 relative with SAH or intracranial aneurysms is not recommended (Level of Evidence: C)" |
| Class IIa |
| "1. Obtaining a family history can be useful to help identify persons who may be at increased risk of stroke (Level of Evidence: A)" |
| Class IIb |
| "1. Referral for genetic counseling may be considered for patients with rare genetic causes of stroke (Level of Evidence: C)" |
| "2. Treatment for certain genetic conditions that pre- dispose to stroke (eg, Fabry disease and enzyme replacement therapy) might be reasonable but has not been shown to reduce risk of stroke, and its effectiveness is unknown (Level of Evidence: C)" |
| "3. Noninvasive screening for unruptured intracranial aneurysms in patients with ADPKD and ≥1 relatives with ADPKD and SAH or intracranial aneurysm may be considered(Level of Evidence: C)" |
| "4. Noninvasive screening for unruptured intracranial aneurysms in patients with ≥2 first-degree relatives with SAH or intracranial aneurysms might be reasonable (Level of Evidence: C)" |
| "5. Noninvasive screening for unruptured intracranial aneurysms in patients with cervical fibromuscular dysplasia may be considered(Level of Evidence: C)" |
| "6. harmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated(Level of Evidence: C)" |
References
- ↑ 2014 AHA/ASA Guidelines for the Primary Prevention of Stroke http://stroke.ahajournals.org/content/early/2014/10/28/STR.00000000000000467 Accessed on November 17, 2016